- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06207474
A Study on BReast Cancer Patient Care Using chAtbot and Video Education for Radiation Therapy (BRAVE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study evaluates the impact of patient management and information provision using educational videos and chatbots on patient experience, satisfaction, and patient psychology in the breast cancer radiation treatment process.
The experiment is designed as (2 (with or without using chatbot) X 2 (with or without using video) to distinguish groups.
There is no separate treatment intervention in addition to use chatbot and video utilization.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Yonsei Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A breast cancer patient scheduled for radiation therapy after radical surgery.
- Subjects must have the cognitive ability to use smartphone.
- Age ≥ 20 year old
Exclusion Criteria:
- Patients with visual or auditory impairment.
- Subjects do not consent to participate in this study.
- Pregnancy, fetus, newborn, underage
- Age ≥ 75 year old
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Video + Chatbot
|
Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of educational videos and interactive chatbot sessions.
|
Other: Video + Paper
|
Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of educational videos and paper materials.
|
Other: Paper + Chatbot
|
Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of paper materials and interactive chatbot sessions.
|
Other: Paper + Paper
|
Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using paper materials.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
APAIS(Amsterdam Preoperative Anxiety and Information Scale)
Time Frame: baseline, before radiation therapy, after all radiation, an average of 1 month
|
The Amsterdam Preoperative Anxiety and Information Scale (APAIS): The APAIS consists of six self-reported items, primarily assessing anxiety associated with anesthesia and surgery.
|
baseline, before radiation therapy, after all radiation, an average of 1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
STAI-X(State-Trait Anxiety Inventory for Adults)
Time Frame: baseline, before radiation therapy, after all radiation, an average of 1 month
|
The STAI is a widely recognized self-report instrument for gauging anxiety levels.
|
baseline, before radiation therapy, after all radiation, an average of 1 month
|
LASA(Linear Analog Scale Assessments)
Time Frame: baseline, before radiation therapy, after all radiation, an average of 1 month
|
LASA is a tool to measure a patient's self-assessment of various aspects of their health and wellbeing.
|
baseline, before radiation therapy, after all radiation, an average of 1 month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yong Bae Kim, Yonsei Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4-2022-0044
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Seagen Inc.CompletedTriple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast NeoplasmsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Celgene CorporationTerminatedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
Providence Health & ServicesBrooklyn ImmunoTherapeutics, LLCActive, not recruitingBreast Neoplasm | Triple Negative Breast Cancer | Breast Neoplasm, MaleUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Dana-Farber Cancer InstituteConquer Cancer FoundationRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Inflammatory Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of BreastUnited States
-
GlaxoSmithKlineCompletedNeoplasms, BreastUnited States, Spain, Israel, Canada, Belgium, United Kingdom, France, Tunisia
-
GlaxoSmithKlineCompletedNeoplasms, BreastUnited States, Canada, Germany, Spain, Taiwan, Belgium, Philippines, Israel, Hong Kong, Thailand, Pakistan, Russian Federation, Italy, Romania, China, France, Peru, United Kingdom, Czech Republic, Australia, Chile, Korea, Republic of and more
Clinical Trials on Video + Chatbot
-
Dana-Farber Cancer InstituteCompletedBreast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate CancerUnited States
-
University of Maryland, College ParkCompletedCervical Cancer | Anal Cancer | Penile CancerUnited States
-
Weill Medical College of Cornell UniversityRecruitingGynecologic Cancer | Hereditary Cancer SyndromeUnited States
-
Sun Yat-sen UniversityRecruiting
-
Cheng-Hsin General HospitalRecruitingLower Urinary Tract Symptoms | Erectile Dysfunction | Benign Prostate EnlargementTaiwan
-
Abramson Cancer Center at Penn MedicineRecruitingHead and Neck Cancer | Lung Cancer | Gastrointestinal CancerUnited States
-
Adonis Hijaz, MDRecruiting
-
University of Social Sciences and Humanities, WarsawMinistry of Science and Higher Education, PolandCompletedDepression | AnxietyPoland
-
University Hospital, ToulouseNot yet recruiting
-
University of ChicagoNorthShore University HealthSystemCompletedDepression, Postpartum | Depression, UnipolarUnited States